e-learning
resources
Virtual 2020
Pre-Congress Content
COPD : inhaled corticosteroids, bronchodilators and eosinophils
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Evaluation of the clinical efficacy of the fluticasone-salmeterol fixed dose combination (FDC) in Greek patients with Chronic Obstructive Pulmonary Disease-AEOLOS study
I. Markou (Pikermi, Greece), S. Tryfon (Thessaloniki, Greece), P. Steiropoulos (Alexandroupolis, Greece), A. Ginis (Pikermi, Greece), A. Athanassiou (Pikermi, Greece), N. Grekas (Pikermi, Greece)
Source:
Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils
Session:
COPD : inhaled corticosteroids, bronchodilators and eosinophils
Session type:
E-poster session
Number:
3245
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Markou (Pikermi, Greece), S. Tryfon (Thessaloniki, Greece), P. Steiropoulos (Alexandroupolis, Greece), A. Ginis (Pikermi, Greece), A. Athanassiou (Pikermi, Greece), N. Grekas (Pikermi, Greece). Evaluation of the clinical efficacy of the fluticasone-salmeterol fixed dose combination (FDC) in Greek patients with Chronic Obstructive Pulmonary Disease-AEOLOS study. 3245
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Cardiovascular safety of fixed dose combination long acting bronchodilators in stable patients with Chronic Obstructive Pulmonary Disease.
Source: International Congress 2018 – Cardiovascular morbidities in COPD
Year: 2018
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
One year change in health status in patients with stable Chronic Obstructive Pulmonary Disease (COPD) under long-acting bronchodilators treatment
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017
Patient-reported outcomes (PROs) and reliever use in Japanese and European patients with chronic obstructive pulmonary disease receiving formoterol 4.5 and 9μg twice daily: Results of the OCEAN phase III study
Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Year: 2010
Microbiome Use to Stratify Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (MUSIC) trial: baseline data and impact of inhaled corticosteroid withdrawal in severe COPD with frequent exacerbations
Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils
Year: 2020
Lung function efficacy of olodaterol QD delivered via Respimat® in COPD patients: Results from two 48-week studies
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Effectiveness of indacaterol with or without tiotropium in patients with moderate or severe chronic obstructive pulmonary disease (COPD) - the GOLDEN II study
Source: International Congress 2014 – Diagnosis and treatment of COPD in primary care
Year: 2014
Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Home management of severe Chronic Obstructive Pulmonary Disease (COPD): results from a randomized controlled study in Italy
Source: International Congress 2019 – Clinical implications of COPD management
Year: 2019
Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three phase III studies
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD)
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Late Breaking Abstract - Inhaled corticosteroids (ICS), blood eosinophils (EOS), and FEV1 decline in patients with Chronic Obstructive Pulmonary Disease in a large UK primary healthcare setting
Source: International Congress 2018 – Epidemiology of COPD : from exarcebations and comorbidities to asthma-COPD overlap syndrome (ACOS)
Year: 2018
Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Sing-a-Lung: Group singing as training modality in pulmonary rehabilitation for patients with Chronic Obstructive Pulmonary Disease (COPD): A multicenter, cluster-randomised, non-inferiority controlled trial
Source: Virtual Congress 2020 – Best abstracts in the field of pulmonary rehabilitation
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept